REMICADE (R) Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis Approval Expands Access to REMICADE for Children Living with Ulcerative Colitis

被引：0
|
作者：
不详
机构：
来源：
PRACTICAL GASTROENTEROLOGY | 2011年 / 35卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：59 / 60
页数：2
相关论文
共 28 条
  • [21] Time to first treatment with biologic agents for ulcerative colitis and Crohn's disease across four Nordic countries: Results from the TRINordic study
    Hoivik, M.
    Lordal, M.
    Burisch, J.
    Langholz, E.
    Knudsen, T.
    Voutilainen, M.
    Moum, B.
    Anisdahl, K.
    Saebo, B.
    Haiko, P.
    Malmgren, C.
    Coskun, M.
    Melberg, H. O.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S060 - S061
  • [22] Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis
    Haynesworth, Austin
    Yeh, Kuan-Hung
    Lee, Han Hee
    Kirkpatrick, Melissa
    Boland, Brigid S.
    Syal, Gaurav
    Xu, Ronghui
    Singh, Siddharth
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (04) : 693 - 701
  • [23] Anti-CBIR1 Is Commonly Detectable in Children with Ulcerative Colitis, But Does Not Predict Disease Course Over the First 2 Years of Treatment
    Markowitz, James
    Mack, David R.
    Leleiko, Neal S.
    Otley, Anthony R.
    Evans, Jonathan S.
    Pfefferkorn, Marian D.
    Oliva-Hemker, Maria
    Crandall, Wallace
    Rosh, Joel R.
    Kappelman, Michael D.
    Keljo, David J.
    Kugathasan, Subra
    Lerer, Trudy
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2009, 136 (05) : A654 - A655
  • [24] Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications
    Tanaka, Tomotaka
    Sugiyama, Shinichiro
    Goishi, Hirokazu
    Kajihara, Tsuyoshi
    Akagi, Morihisa
    Miura, Toshio
    BMC GASTROENTEROLOGY, 2013, 13
  • [25] Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications
    Tomotaka Tanaka
    Shinichiro Sugiyama
    Hirokazu Goishi
    Tsuyoshi Kajihara
    Morihisa Akagi
    Toshio Miura
    BMC Gastroenterology, 13
  • [26] A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
    Mantzaris, Gerassimos J.
    Bressler, Brian
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Colby, Chris
    Lopez, Claudia
    Saha, Sumit
    Kifnidi, Christina
    Agboton, Christian
    Adsul, Shashi
    Demuth, Dirk
    Luo, Michelle
    Wang, Song
    Yarur, Andres J.
    GASTROENTEROLOGY, 2020, 158 (06) : S405 - S405
  • [27] A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
    Mantzaris, G.
    Bressler, B.
    Kopylov, U.
    Bassel, M.
    Brett, N.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Yarur, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S092 - S094
  • [28] Treatment of corticosteroid naive children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications
    Tanaka, T.
    Sugiyama, S.
    Goishi, H.
    Kajihara, T.
    Akagi, M.
    Miura, T.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S193 - S193
123